Contact
searchSearch
HMP Global
Login
Conference Coverage
Novel KIT6 Inhibitor Plus Fulvestrant Shows Antitumor Activity Among Heavily Pretreated Patients With ER-Positive, HER2-Negative Metastatic Breast Cancer
03/10/2025
The first-in-class KIT6 inhibitor PF-07248144 plus fulvestrant demonstrated durable response and tolerable safety among patients with ER-positive, HER2-negative metastatic breast cancer who had progressed on or after CDK4/6 inhibition and...
The first-in-class KIT6 inhibitor PF-07248144 plus fulvestrant demonstrated durable response and tolerable safety among patients with ER-positive, HER2-negative metastatic breast cancer who had progressed on or after CDK4/6 inhibition and...
The first-in-class KIT6...
03/10/2025
Oncology
Conference Coverage
Patritumab Deruxtecan Shows Promise for Advanced HR-Positive, HER2-Negative Breast Cancer
03/10/2025
According to results from the phase 2 ICARUS-BREAST01 trial, patritumab deruxtecan showed promising efficacy and tolerable safety for patients with HR-positive, HER2-negative locally advanced and metastatic breast cancer who had progressed on...
According to results from the phase 2 ICARUS-BREAST01 trial, patritumab deruxtecan showed promising efficacy and tolerable safety for patients with HR-positive, HER2-negative locally advanced and metastatic breast cancer who had progressed on...
According to results from the...
03/10/2025
Oncology
Conference Coverage
Real-World Safety, Efficacy of Sacituzumab Govitecan for Metastatic Triple-Negative Breast Cancer
03/07/2025
A retrospective analysis of real-world data found that sacituzumab govitecan was safe and effective for patients with metastatic triple-negative breast cancer.
A retrospective analysis of real-world data found that sacituzumab govitecan was safe and effective for patients with metastatic triple-negative breast cancer.
A retrospective analysis of...
03/07/2025
Oncology
William Gradishar, MD, Robert H Lurie Comprehensive Cancer Center
Videos
Extended Endocrine Therapy for Patients With Hormone Receptor-Positive, Early-Stage Breast Cancer
03/06/2025
William Gradishar, MD, discusses the issue of endocrine therapy, and extended endocrine therapy, for patients with hormone receptor-positive breast cancer.
William Gradishar, MD, discusses the issue of endocrine therapy, and extended endocrine therapy, for patients with hormone receptor-positive breast cancer.
William Gradishar, MD, discusses...
03/06/2025
Oncology
DrL
Podcasts
Dr Loprinzi Reviews Hot Flash Treatment Strategies in BC, Part II
03/15/2022
In part two of this interview, Charles Loprinzi, MD, Mayo Clinic, highlights some non-estrogenic approaches to hot flash management for patients with breast cancer, presented at the 39th Annual Miami Breast Cancer Conference.
In part two of this interview, Charles Loprinzi, MD, Mayo Clinic, highlights some non-estrogenic approaches to hot flash management for patients with breast cancer, presented at the 39th Annual Miami Breast Cancer Conference.
In part two of this interview,...
03/15/2022
Oncology
Dr L
Podcasts
Dr Loprinzi Reviews Hot Flash Treatment Strategies in BC, Part I
03/14/2022
In part one of this interview, Charles Loprinzi, MD, Mayo Clinic, highlights some non-estrogenic approaches to hot flash management for patients with breast cancer, presented at the 39th Annual Miami Breast Cancer Conference.
In part one of this interview, Charles Loprinzi, MD, Mayo Clinic, highlights some non-estrogenic approaches to hot flash management for patients with breast cancer, presented at the 39th Annual Miami Breast Cancer Conference.
In part one of this interview,...
03/14/2022
Oncology
Dr.K
Conference Insider
Eribulin Yields Promise in Previously Treated mBC
03/14/2022
Investigators reveal eribulin may be an effective agent for previously treated metastatic breast cancer, presented at the 39th Annual Miami Breast Cancer Conference.
Investigators reveal eribulin may be an effective agent for previously treated metastatic breast cancer, presented at the 39th Annual Miami Breast Cancer Conference.
Investigators reveal eribulin...
03/14/2022
Oncology
Dr M
Conference Insider
Talazoparib Reveals Clinical Benefit in HER2-Negative, aBC
03/14/2022
Phase 3 EMBRACA trial results reveal patients with HER2-negative, locally advanced or metastatic breast cancer harboring germline BRCA (gBRCA) mutations treated with talazoparib, displayed clinical benefit in both a real-world analyses...
Phase 3 EMBRACA trial results reveal patients with HER2-negative, locally advanced or metastatic breast cancer harboring germline BRCA (gBRCA) mutations treated with talazoparib, displayed clinical benefit in both a real-world analyses...
Phase 3 EMBRACA trial results...
03/14/2022
Oncology
Retooling Precision Oncology for True Equity of Cancer Care
Videos
Retooling Precision Oncology for True Equity of Cancer Care
03/24/2021
Olufunmilayo Olopade, MD, FACP, discusses the overhaul of precision oncology for true equity in cancer care, and brings focus to patient populations who have been understudied.
Olufunmilayo Olopade, MD, FACP, discusses the overhaul of precision oncology for true equity in cancer care, and brings focus to patient populations who have been understudied.
Olufunmilayo Olopade, MD, FACP,...
03/24/2021
Oncology
Dr Lucci Discusses MRM in De Novo for Stage IV Inflammatory Breast Cancer
Videos
Dr Lucci Discusses MRM in De Novo for Stage IV Inflammatory Breast Cancer
03/09/2021
Anthony Lucci, MD, highlights the significant results of a study on the role of MRM in patients with de novo stage IV inflammatory breast cancer.
Anthony Lucci, MD, highlights the significant results of a study on the role of MRM in patients with de novo stage IV inflammatory breast cancer.
Anthony Lucci, MD, highlights...
03/09/2021
Oncology
Dr Brufsky Discusses Evolving Strategies in Early-Stage TNBC Treatment
Videos
Dr Brufsky Discusses Evolving Strategies in Early-Stage TNBC Treatment
03/04/2021
Adam Brufsky, MD, PhD, discusses evolving strategies in neoadjuvant/adjuvant treatment of early-stage TNBC.
Adam Brufsky, MD, PhD, discusses evolving strategies in neoadjuvant/adjuvant treatment of early-stage TNBC.
Adam Brufsky, MD, PhD, discusses...
03/04/2021
Oncology
Dr Hunt Talks Neoadjuvant Endocrine Therapy for Breast Cancer
Videos
Dr Hunt Talks Neoadjuvant Endocrine Therapy for Breast Cancer
03/03/2021
At the annual Miami Breast Cancer Conference, Kelly Hunt, MD, discussed the use of neoadjuvant endocrine therapy for patients with breast cancer.
At the annual Miami Breast Cancer Conference, Kelly Hunt, MD, discussed the use of neoadjuvant endocrine therapy for patients with breast cancer.
At the annual Miami Breast...
03/03/2021
Oncology
Dr Chagpar Discusses Neoadjuvant Chemo for cN0 Breast Cancer
Videos
Dr Chagpar Discusses Neoadjuvant Chemo for cN0 Breast Cancer
03/01/2021
Anees Chagpar, MD, discusses her presentation on neoadjuvant chemo for cN0 breast cancer from the Miami Breast Cancer Conference.
Anees Chagpar, MD, discusses her presentation on neoadjuvant chemo for cN0 breast cancer from the Miami Breast Cancer Conference.
Anees Chagpar, MD, discusses her...
03/01/2021
Oncology
Experts Convene to Discuss Hot Topics in the Breast Cancer Space
Videos
Experts Convene to Discuss Hot Topics in the Breast Cancer Space
02/25/2021
Anees Chagpar, MD, highlights notable research and presentations from the annual Miami Breast Cancer Conference.
Anees Chagpar, MD, highlights notable research and presentations from the annual Miami Breast Cancer Conference.
Anees Chagpar, MD, highlights...
02/25/2021
Oncology
Kevin Kalinsky, MD, MS, on the Importance of Gene-Profiling for Early-Stage Breast Cancer
Podcasts
Kevin Kalinsky, MD, MS, on the Importance of Gene-Profiling for Early-Stage Breast Cancer
03/09/2020
Dr Kalinsky discusses why gene profiling plays such an important role in the management of patients with early-stage breast cancer.
Dr Kalinsky discusses why gene profiling plays such an important role in the management of patients with early-stage breast cancer.
Dr Kalinsky discusses why gene...
03/09/2020
Oncology
Neoadjuvant Endocrine Therapy Less Toxic Than Chemo in Advanced, ER-Positive Breast Cancer
Interview
Neoadjuvant Endocrine Therapy Less Toxic Than Chemo in Advanced, ER-Positive Breast Cancer
03/03/2020
Aditya Bardia, MD, MPH, discusses the advancing therapy landscape for locally advanced, ER-positive breast cancer, and challenges associated with management of this disease.
Aditya Bardia, MD, MPH, discusses the advancing therapy landscape for locally advanced, ER-positive breast cancer, and challenges associated with management of this disease.
Aditya Bardia, MD, MPH,...
03/03/2020
Oncology
News
Palbociclib Combination Regimen Effective in Treatment of ER+, HER2- Breast Cancer
03/16/2018
First-line palbociclib plus letrozole demonstrated significant efficacy in patients with ER-positive, HER2-negative breast cancer.
First-line palbociclib plus letrozole demonstrated significant efficacy in patients with ER-positive, HER2-negative breast cancer.
First-line palbociclib plus...
03/16/2018
Oncology
News
Dual Targeting Promising for HER2+/HR+ Breast Cancer
03/16/2018
The discovery of crosstalk between HER2 and HR pathways has led to the promising strategy of dual targeting regimens.
The discovery of crosstalk between HER2 and HR pathways has led to the promising strategy of dual targeting regimens.
The discovery of crosstalk...
03/16/2018
Oncology
News
Ribociclib Improves PFS in Premenopausal Advanced Breast Cancer
03/16/2018
Ribociclib improves PFS in premenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer.
Ribociclib improves PFS in premenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer.
Ribociclib improves PFS in...
03/16/2018
Oncology

Experts from across the globe gather in Miami to discover and share groundbreaking research among members of the cancer care community who diagnose and treat patients with breast cancer.

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use